Incremental Predictive Value and Representation of Transcriptomic Features for Immunotherapy Response in Advanced Urothelial Carcinoma
- 1Stony Brook University
Abstract
Transcriptomic profiling may improve immunotherapy response prediction, but its incremental value beyond established clinical and tumor biomarkers is unclear. In 298 patients with advanced urothelial carcinoma from IMvigor210, an atezolizumab (PD-L1 inhibitor) trial, we compared knowledge-guided tumor microenvironment gene-set features with data-driven transcriptome-wide gene selection. Knowledge-guided features improved AUPRC by 0.058 beyond clinical variables alone, with smaller gains after including standard biomarkers (TMB, PD-L1; +0.011) and research-enriched biomarkers (neoantigen burden, immune phenotype; +0.016). Data-driven gene selection was unstable across folds (mean Jaccard similarity, 0.227) and, under the clinical-plus-biomarker baseline, yielded an AUPRC 0.150 lower than the knowledge-guided representation. Despite this instability, IL-6/JAK/STAT3 signaling was the most recurrent Hallmark pathway, suggesting pathway-level biological convergence. External evaluation showed a similar pattern: knowledge-guided features improved AUPRC by 0.128 over clinical variables vs. 0.019 over clinical-plus-biomarker baseline. These findings support biologically informed transcriptomic representation when molecular profiling adds value beyond established biomarkers.
Related
- Circulating and tumor microenvironment immunomarkers associate with immunotherapy efficacy in advanced bladder urothelial carcinoma: an exploratory multicenter study integrating genomic and immunophenotypic profiling
- 455 Second primary malignancy risk in the immunotherapy era among urothelial carcinoma survivors: a SEER population-based analysis
- Integrated Transcriptomic and Network Analysis Identifies Diagnostic and Immune-Associated Hub Genes in Urothelial Carcinoma
- Peristomal skin and subcutaneous tissue metastasis of urothelial carcinoma and successful treatment with immunotherapy: A 5-year follow-up case report.
- Incremental Predictive Value of Post-Baseline Surgery and the Impact of Temporal Coding on Mortality Associations in Infective Endocarditis: A Temporally Validated Cohort Study
BibTeX
@misc{han2026incremental,
title = {{Incremental Predictive Value and Representation of Transcriptomic Features for Immunotherapy Response in Advanced Urothelial Carcinoma}},
author = {G. Y. Han and H. Tai and F. Wang},
howpublished = {medRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.14.26363060},
url = {https://www.medrxiv.org/content/10.64898/2026.09.14.26363060v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - Incremental Predictive Value and Representation of Transcriptomic Features for Immunotherapy Response in Advanced Urothelial Carcinoma
AU - G. Y. Han
AU - H. Tai
AU - F. Wang
PY - 2026
DA - 2026/09/14
PB - medRxiv
DO - 10.64898/2026.09.14.26363060
UR - https://www.medrxiv.org/content/10.64898/2026.09.14.26363060v1
AB - Transcriptomic profiling may improve immunotherapy response prediction, but its incremental value beyond established clinical and tumor biomarkers is unclear. In 298 patients with advanced urothelial carcinoma from IMvigor210, an atezolizumab (PD-L1 inhibitor) trial, we compared knowledge-guided tumor microenvironment gene-set features with data-driven transcriptome-wide gene selection. Knowledge-guided features improved AUPRC by 0.058 beyond clinical variables alone, with smaller gains after including standard biomarkers (TMB, PD-L1; +0.011) and research-enriched biomarkers (neoantigen burden, immune phenotype; +0.016). Data-driven gene selection was unstable across folds (mean Jaccard similarity, 0.227) and, under the clinical-plus-biomarker baseline, yielded an AUPRC 0.150 lower than the knowledge-guided representation. Despite this instability, IL-6/JAK/STAT3 signaling was the most recurrent Hallmark pathway, suggesting pathway-level biological convergence. External evaluation showed a similar pattern: knowledge-guided features improved AUPRC by 0.128 over clinical variables vs. 0.019 over clinical-plus-biomarker baseline. These findings support biologically informed transcriptomic representation when molecular profiling adds value beyond established biomarkers.
ER -